Search

Your search keyword '"Cornely, Oliver A."' showing total 2,334 results
Start Over Author "Cornely, Oliver A."
2,334 results on '"Cornely, Oliver A."'

157. Age, Successive Waves, Immunization, and Mortality in Elderly COVID-19 Haematological Patients: EPICOVIDEHA Findings

Author

ROSSI, Giuseppe, primary, SALMANTON-GARCÍA, Jon, additional, CATTANEO, Chiara, additional, MARCHESI, Francesco, additional, DÁVILA-VALLS, Julio, additional, MARTÍN-PÉREZ, Sonia, additional, ITRI, Federico, additional, LÓPEZ-GARCÍA, Alberto, additional, GLENTHØJ, Andreas, additional, SILVA, Maria GOMES DA, additional, BESSON, Caroline, additional, MARCHETTI, Monia, additional, WEINBERGEROVÁ, Barbora, additional, JAKSIC, Ozren, additional, JIMÉNEZ, Moraima, additional, BILGIN, Yavuz M., additional, DOESUM, Jaap VAN, additional, FARINA, Francesca, additional, ŽÁK, Pavel, additional, VERGA, Luisa, additional, COLLINS, Graham P., additional, BONUOMO, Valentina, additional, PRAET, Jens VAN, additional, NUCCI, Marcio, additional, MEERS, Stef, additional, ESPIGADO, Ildefonso, additional, FRACCHIOLLA, Nicola S., additional, VALKOVIĆ, Toni, additional, POULSEN, Christian Bjørn, additional, ČOLOVIĆ, Natasha, additional, DRAGONETTI, Giulia, additional, LEDOUX, Marie-Pierre, additional, TASCINI, Carlo, additional, BUQUICCHIO, Caterina, additional, BLENNOW, Ola, additional, PASSAMONTI, Francesco, additional, MACHADO, Marina, additional, LABRADOR, Jorge, additional, DUARTE, Rafael F., additional, SCHÖNLEIN, Martin, additional, PREZIOSO, Lucia, additional, FALCES-ROMERO, Iker, additional, KULASEKARARAJ, Austin, additional, GARCIA-VIDAL, Carolina, additional, FERNÁNDEZ, Noemí, additional, ABU-ZEINAH, Ghaith, additional, ORMAZABAL-VÉLEZ, Irati, additional, ADŽIĆ-VUKIČEVIĆ, Tatjana, additional, PIUKOVICS, Klára, additional, STOMA, Igor, additional, CUCCARO, Annarosa, additional, MAGLIANO, Gabriele, additional, SZOTKOWSKI, Tomáš, additional, GONZÁLEZ-LÓPEZ, Tomás-José, additional, EL-ASHWAH, Shaimaa, additional, BERGANTIM, Rui, additional, SILI, Uluhan, additional, MAERTENS, Johan, additional, DEMIRKAN, Fatih, additional, RAMÓN, Cristina DE, additional, PETZER, Verena, additional, PRINCIPE, Maria Ilaria DEL, additional, NAVRÁTIL, Milan, additional, DARGENIO, Michelina, additional, SEVAL, Guldane Cengiz, additional, SAMARKOS, Michail, additional, RÁČIL, Zdeněk, additional, PINCZÉS, László Imre, additional, LAHMER, Tobias, additional, BUSCA, Alessandro, additional, MÉNDEZ, Gustavo-Adolfo, additional, VENA, Antonio, additional, BIERNAT, Monika M., additional, MERELLI, Maria, additional, CALBACHO, Maria, additional, BARAĆ, Aleksandra, additional, BAVASTRO, Martina, additional, LIMONGELLI, Alessandro, additional, ILHAN, Osman, additional, WOLF, Dominik, additional, ÇOLAK, Gökçe Melis, additional, GARCÍA-SANZ, Ramón, additional, EMARAH, Ziad, additional, MIŠKOVIĆ, Bojana, additional, GRÄFE, Stefanie, additional, MLADENOVIĆ, Miloš, additional, AIELLO, Tommaso Francesco, additional, NÚÑEZ-MARTÍN-BUITRAGO, Lucía, additional, NORDLANDER, Anna, additional, ARELLANO, Elena, additional, ZAMBROTTA, Giovanni Paolo Maria, additional, AMMATUNA, Emanuele, additional, CABIRTA, Alba, additional, SACCHI, Maria Vittoria, additional, RODRIGUES, Raquel NUNES, additional, HERSBY, Ditte Stampe, additional, HANAKOVA, Michaela, additional, RAHIMLI, Laman, additional, CORDOBA, Raul, additional, CORNELY, Oliver A., additional, and PAGANO, Livio, additional

Published
2023
Full Text
View/download PDF

159. Clostridioides difficile infection (CDI): A pan-European multi-center cost and resource utilization study, results from the Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI)

Author

Academic Partners, Bonten, Marc, Davies, Kerrie A., Wilcox, Mark H., Kuijper, Ed, Rupnik, Maja, Wingen-Heimann, Sebastian, Tacconelli, Evelina, Vilken, Tuba, Petrosillo, Nicola, EFPIA Partners, Pfizer Ltd, GlaxoSmithKline, bioMérieux, Pasteur, Sanofi, Da Volterra, The Management Board of COMBACTE-CDI, Cleuziat, Philippe, Webber, Chris, Wingen-Heimann, Sebastian M., Davies, Kerrie, Viprey, Virginie F., Davis, Georgina, Vehreschild, Maria J.G.T., Lurienne, Lise, Bandinelli, Pierre-Alain, Cornely, Oliver A., Hopff, Sina M., and Vehreschild, Jörg Janne

Published
2023
Full Text
View/download PDF

165. Blutstrominfektionen

Author

Cornely, Oliver A., primary, Köhler, Philipp, additional, Mellinghoff, Sibylle, additional, Rolling, Thierry, additional, Rieg, Siegbert, additional, and Wichmann, Dominic, additional

Published
2021
Full Text
View/download PDF

168. Infektionen bei Immunschwäche

Author

Claßen, Annika Y., primary, Cornely, Oliver A., additional, Hanses, Frank, additional, Köhler, Philipp, additional, Mellinghoff, Sibylle, additional, Vehreschild, Jörg Janne, additional, and Witzke, Oliver, additional

Published
2021
Full Text
View/download PDF

169. Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion

Author

Verweij, Paul E., Rijnders, Bart J. A., Brüggemann, Roger J. M., Azoulay, Elie, Bassetti, Matteo, Blot, Stijn, Calandra, Thierry, Clancy, Cornelius J., Cornely, Oliver A., Chiller, Tom, Depuydt, Pieter, Giacobbe, Daniele Roberto, Janssen, Nico A. F., Kullberg, Bart-Jan, Lagrou, Katrien, Lass-Flörl, Cornelia, Lewis, Russell E., Liu, Peter Wei-Lun, Lortholary, Olivier, Maertens, Johan, Martin-Loeches, Ignacio, Nguyen, M. Hong, Patterson, Thomas F., Rogers, Thomas R., Schouten, Jeroen A., Spriet, Isabel, Vanderbeke, Lore, Wauters, Joost, and van de Veerdonk, Frank L.

Published
2020
Full Text
View/download PDF

174. Erreger

Author

Ewig, Santiago, Cornely, Oliver, Gatermann, Sören, and Ewig, Santiago, editor

Published
2018
Full Text
View/download PDF

178. Herpes Viruses

Author

Sprute, Rosanne, primary, Koehler, Philipp, additional, and Cornely, Oliver A., additional

Published
2020
Full Text
View/download PDF

179. Incidence of Cyp51 A key mutations in Aspergillus fumigatus-a study on primary clinical samples of immunocompromised patients in the period of 1995-2013.

Author

Spiess, Birgit, Postina, Patricia, Reinwald, Mark, Cornely, Oliver A, Hamprecht, Axel, Hoenigl, Martin, Lass-Flörl, Cornelia, Rath, Peter-Michael, Steinmann, Jörg, Miethke, Thomas, Lauten, Melchior, Will, Silke, Merker, Natalia, Hofmann, Wolf-Karsten, and Buchheidt, Dieter

Subjects
Humans, Aspergillus fumigatus, Aspergillosis, Azoles, Cytochrome P-450 Enzyme System, Fungal Proteins, Antifungal Agents, Microbial Sensitivity Tests, Sensitivity and Specificity, Polymerase Chain Reaction, Drug Resistance, Fungal, Immunocompromised Host, Mutation, General Science & Technology
Abstract

As the incidence of azole resistance in Aspergillus fumigatus is rising and the diagnosis of invasive aspergillosis (IA) in immunocompromised patients is rarely based on positive culture yield, we screened our Aspergillus DNA sample collection for the occurrence of azole resistance mediating cyp51 A key mutations. Using two established, a modified and a novel polymerase chain reaction (PCR) assays followed by DNA sequence analysis to detect the most frequent mutations in the A. fumigatus cyp51 A gene conferring azole resistance (TR34 (tandem repeat), L98H and M220 alterations). We analyzed two itraconazole and voriconazole and two multi-azole resistant clinical isolates and screened 181 DNA aliquots derived from clinical samples (blood, bronchoalveolar lavage (BAL), biopsies, cerebrospinal fluid (CSF)) of 155 immunocompromised patients of our Aspergillus DNA sample collection, previously tested positive for Aspergillus DNA and collected between 1995 and 2013. Using a novel PCR assay for the detection of the cyp51 A 46 bp tandem repeat (TR46) directly from clinical samples, we found the alteration in a TR46/Y121F/T289A positive clinical isolate. Fifty stored DNA aliquots from clinical samples were TR46 negative. DNA sequence analysis revealed a single L98H mutation in 2010, two times the L98H alteration combined with TR34 in 2011 and 2012 and a so far unknown N90K mutation in 1998. In addition, four clinical isolates were tested positive for the TR34/L98H combination in the year 2012. We consider our assay of epidemiological relevance to detect A. fumigatus azole resistance in culture-negative clinical samples of immunocompromised patients; a prospective study is ongoing.

Published
2014

180. RSV vaccination strategies for high-risk patients 2023: a collaborative position paper by leading German medical societies and organizations.

Author

Addo, Marylyn, Cornely, Oliver, Denkinger, Michael, Ertl, Georg, Herold, Susanne, Pletz, Mathias, Rohde, Gernot, Welte, Tobias, Windisch, Wolfram, and Witzenrath, Martin

Subjects
LUNG disease prevention, CARDIOVASCULAR diseases risk factors, VACCINES, IMMUNIZATION, RESPIRATORY syncytial virus infections, MEDICAL societies, OLD age
Abstract

Respiratory syncytial virus (RSV) inflicts severe illness and courses of infections not only in neonates, infants, and young children, but also causes significant morbidity and mortality in older adults and in people with immunosuppression, hemato-oncologic disease, chronic lung disease, or cardiovascular disease. In June and August 2023, effective vaccines against RSV were approved for the first time by the European Medicines Agency (EMA) for the EU. The respective pivotal studies showed a very high efficacy of the vaccine in preventing severe RSV-associated respiratory infections. At this point, use of the respective vaccines is restricted to persons aged 60 years or older, according to the registration studies. We therefore recommend use of the vaccination in persons aged 60 years or older. In addition, we recommend use of the vaccination in adults of any age with severe pulmonary or cardiovascular pre-existing conditions, as well as in adults with significant immune compromise, after individual consultation with the treating physician. Cost coverage can be applied for individually with the responsible health insurance company. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

181. Questioning the 14-day dogma in candidemia treatment duration.

Author

Salmanton-García, Jon, Reinhold, Ilana, Prattes, Juergen, Bekaan, Nico, Koehler, Philipp, and Cornely, Oliver A.

Subjects
CANDIDEMIA, TREATMENT duration, THERAPEUTICS, DOGMA, DRUG resistance in microorganisms
Abstract

The growing threat of antimicrobial resistance (AMR) is a global concern. With AMR directly causing 1.27 million deaths in 2019 and projections of up to 10 million annual deaths by 2050, optimising infectious disease treatments is imperative. Prudent antimicrobial use, including treatment duration, can mitigate AMR emergence. This is particularly critical in candidemia, a severe condition with a 45% crude mortality rate, as the 14-day minimum treatment period has not been challenged in randomised comparison. A comprehensive literature search was conducted in August 2023, revealing seven original articles and two case series discussing treatment durations of less than 14 days for candidemia. No interventional trials or prospective observational studies assessing shorter durations were found. Historical studies showed varying candidemia treatment durations, questioning the current 14-day minimum recommendation. Recent research observed no significant survival differences between patients receiving shorter or longer treatment, emphasising the need for evidence-based guidance. Treatment duration reduction post-blood culture clearance could decrease exposure to antifungal drugs, limiting selection pressure, especially in the context of emerging multiresistant Candida species. Candidemia's complexity, emerging resistance and potential for shorter in-hospital stays underscore the urgency of refining treatment strategies. Evidence-driven candidemia treatment durations are imperative to balance efficacy with resistance prevention and ensure the longevity of antifungal therapies. Further research and clinical trials are needed to establish evidence-based guidelines for candidemia treatment duration. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

182. The Nairobi Declaration 2023: A commitment to address deadly yet neglected fungal diseases in Africa.

Author

Osaigbovo, Iriagbonse I, Govender, Nelesh P, Jordan, Alexander M, Bongomin, Felix, Meya, David B, Kanyua, Alice, Mashedi, Olga M, Koffi, David, Loyse, Angela, Sturny-Leclère, Aude, Gangneux, Jean-Pierre, Denning, David W, Chiller, Tom, Cornely, Oliver A, and Oladele, Rita O

Abstract

On May 30th and 31st, 2023, delegates representing various African subregions, together with global representatives from the International Society of Human and Animal Mycology (ISHAM), the European Confederation of Medical Mycology (ECMM), the United States Centre for Disease Control and Prevention (CDC), and Global Action for Fungal Infections (GAFFI), convened in Nairobi, Kenya under the aegis of the Pan African Mycology Working Group, a working group of ISHAM. The meeting objectives were, amongst others, to deliberate on a continental response to the World Health Organisation Fungal Priority Pathogen List and facilitate interaction between global and regional leaders. Country delegates and international speakers addressed Africa's fungal disease burden; capacity for diagnosis and management; ongoing surveillance; knowledge gaps and trends in invasive fungal diseases such as Candida auris , mucormycosis, aspergillosis, and Acquired Immune Deficiency Syndrome (AIDS)-related mycoses; and current laboratory practice. During the technical sessions, expert panels deliberated on establishing and financing of national/regional surveillance networks for mycoses; establishing and sustaining African-led collaborations; expanding on existing laboratory and point-of-care diagnostic capacity as well as planning a mycology reference laboratory service and network in Africa. The meeting also highlighted successful African-led collaborations, capacity building, and clinical trial initiatives. The meeting conclusions informed the resolutions of the Nairobi Declaration calling for improved awareness; strong collaborations between clinical and laboratory teams across Africa; improved fungal disease surveillance within the continent; access to antifungals and diagnostics; and leveraging qualified human resources for mycology present within and outside Africa to facilitate trainings, collaborations, and exchanges. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

183. Laboratory and clinical management capacity for invasive fungal infections: the Italian landscape

Author

Vena, Antonio, primary, Bassetti, Matteo, additional, Mezzogori, Laura, additional, Marchesi, Francesco, additional, Hoenigl, Martin, additional, Giacobbe, Daniele Roberto, additional, Corcione, Silvia, additional, Bartoletti, Michele, additional, Stemler, Jannik, additional, Pagano, Livio, additional, Cornely, Oliver A., additional, and Salmanton-García, Jon, additional

Published
2023
Full Text
View/download PDF

184. The Austrian landscape of diagnostic capacity and access to treatment for invasive fungal infections

Author

Salmanton‐García, Jon, primary, Hoenigl, Martin, additional, Salzer, Helmut J. F., additional, Lackner, Michaela, additional, Prattes, Juergen, additional, Dichtl, Karl, additional, Winkler‐Zamani, Markus, additional, Krause, Robert, additional, Stemler, Jannik, additional, Lass‐Flörl, Cornelia, additional, Cornely, Oliver A., additional, and Willinger, Birgit, additional

Published
2023
Full Text
View/download PDF

185. PB2586: PASSIVE PREEXPOSURE IMMUNIZATION BY TIXAGEVIMAB/CILGAVIMAB IN COVID 19 INFECTED HEMATOLOGICAL MALIGNANCY OF EPICOVIDHEA SURVEY

Author

Buquicchio, Caterina, primary, Salmanton-García, Jon, additional, Marchesi, Francesco, additional, Itri, Federico, additional, Besson, Caroline, additional, Martín-Pérez, Sonia, additional, Dávila-Valls, Julio, additional, Fianchi, Luana, additional, Rahimli, Laman, additional, Tarantini, Giuseppe, additional, Grifoni, Federica Irene, additional, Labrador, Jorge, additional, Cordoba, Raul, additional, Lopez-Garcia, Alberto, additional, Fracchiolla, Nicola Stefano, additional, Farina, Francesca, additional, Cornely, Oliver A., additional, and Pagano, Livio, additional

Published
2023
Full Text
View/download PDF

187. S292: NIRMATRELVIR/RITONAVIR IN COVID-19 PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES: A REPORT FROMTHE EPICOVIDEHA REGISTRY

Author

Salmanton-García, Jon, primary, Marchesi, Francesco, additional, Gomes Da Silva, Maria, additional, Farina, Francesca, additional, Dávila-Valls, Julio, additional, Bilgin, Yavuz M., additional, Glenthøj, Andreas, additional, Falces-Romero, Iker, additional, Van Doesum, Jaap, additional, Labrador, Jorge, additional, Buquicchio, Caterina, additional, EL-Ashwah, Shaimaa, additional, Petzer, Verena, additional, VAN Praet, Jens, additional, Schönlein, Martin, additional, Dargenio, Michelina, additional, Méndez, Gustavo-Adolfo, additional, Meers, Stef, additional, Itri, Federico, additional, Giordano, Antonio, additional, Imre Pinczes, Laszlo, additional, Espigado, Ildefonso, additional, Stojanoski, Zlate, additional, Lopez-Garcia, Alberto, additional, Prezioso, Lucia, additional, Jaksic, Ozren, additional, Vena, Antonio, additional, Stefano Fracchiolla, Nicola, additional, Jose Gonzalez-Lopez, Tomas, additional, Čolović, Natasa, additional, Delia, Mario, additional, Weinbergerová, Barbora, additional, Marchetti, Monia, additional, Marques DE Almeida, Joyce, additional, Finizio, Olimpia, additional, Besson, Caroline, additional, Biernat, Monika M., additional, Valkovic, Toni, additional, Lahmer, Tobias, additional, Cuccaro, Annarosa, additional, Ormazabal Velez, Irati, additional, Batinic, Josip, additional, Fernández, Noemí, additional, de Jonge, Nick, additional, Tascini, Carlo, additional, Anastasopoulou, Amalia N., additional, Duléry, Rémy, additional, Ilaria DEL Principe, Maria, additional, Plantefeve, Gaëtan, additional, Virgilio Papa, Mario, additional, Nucci, Marcio, additional, Carmen Jimenez Balarezo, Moraima, additional, Aujayeb, Avinash, additional, Angel Hernandez Rivas, Jose, additional, Merelli, Maria, additional, Cattaneo, Chiara, additional, Blennow, Ola, additional, Nordlander, Anna, additional, Cabirta, Alba, additional, Varricchio, Gina, additional, Vittoria Sacchi, Maria, additional, Cordoba, Raul, additional, Arellano, Elena, additional, Gräfe, Stefanie, additional, Wolf, Dominik, additional, Emarah, Ziad, additional, Ammatuna, Emanuele, additional, Stampe Hersby, Ditte, additional, Martín-Pérez, Sonia, additional, Nunes Rodrigues, Raquel, additional, Rahimli, Laman, additional, Pagano, Livio, additional, and Cornely, Oliver A., additional

Published
2023
Full Text
View/download PDF

189. P1521: IMPROVED CLINICAL OUTCOME OF COVID-19 IN HAEMATOLOGIC MALIGNANCY PATIENTS RECEIVING A FOURTH DOSE OF ANTI-SARS-COV-2 VACCINE: AN EPICOVIDEHA REPORT

Author

Salmanton-García, Jon, primary, Marchesi, Francesco, additional, Glenthøj, Andreas, additional, Bilgin, Yavuz M., additional, Praet, Jens VAN, additional, Dávila-Valls, Julio, additional, Martín-Pérez, Sonia, additional, Labrador, Jorge, additional, Van Doesum, Jaap, additional, Falces-Romero, Iker, additional, Farina, Francesca, additional, Schönlein, Martin, additional, Besson, Caroline, additional, Petzer, Verena, additional, Espigado, Ildefonso, additional, Dargenio, Michelina, additional, Aujayeb, Avinash, additional, Sili, Uluhan, additional, Serrano, Laura, additional, Pinczes, Laszlo Imre, additional, de Jonge, Nick, additional, Soto-Silva, Andrés, additional, Buquicchio, Caterina, additional, Prezioso, Lucia, additional, Marchetti, Monia, additional, Meers, Stef, additional, Busca, Alessandro, additional, Corradini, Paolo, additional, Hoenigl, Martin, additional, Koehler, Philipp, additional, Rahimli, Laman, additional, Melis Çolak, Gökçe, additional, Arellano, Elena, additional, Wolf, Dominik, additional, Gräfe, Stefanie, additional, Ammatuna, Emanuele, additional, Venemyr, Caroline Berg, additional, Cornely, Oliver A., additional, and Pagano, Livio, additional

Published
2023
Full Text
View/download PDF

190. P1514: MOLNUPIRAVIR COMPARED TO NIRMATRELVIR/RITONAVIR FOR COVID-19 IN HIGH-RISK PATIENTS WITH HAEMATOLOGICAL MALIGNANCY IN EUROPE. A MATCHED-PAIRED ANALYSIS FROM THE EPICOVIDEHA REGISTRY

Author

Salmanton-García, Jon, primary, Marchesi, Francesco, additional, Weinbergerová, Barbora, additional, Buquicchio, Caterina, additional, Čolović, Natasa, additional, Praet, Jens VAN, additional, Koehler, Philipp, additional, Falces-Romero, Iker, additional, Farina, Francesca, additional, Itri, Federico, additional, Romano, Alessandra, additional, Pagano, Livio, additional, and Cornely, Oliver A., additional

Published
2023
Full Text
View/download PDF

191. P586: POTENTIAL DRUG-DRUG INTERACTIONS OF ANTIFUNGAL PROPHYLAXIS AND MIDOSTAURIN IN FLT3-MUTATED ACUTE MYELOID LEUKEMIA – CLINICAL IMPLICATIONS OF THERAPEUTIC DRUG MONITORING

Author

Joisten, Carolin, primary, Müller, Carsten, additional, Mellinghoff, Sibylle, additional, Maurer, Christian, additional, Kreuzer, Karl-Anton, additional, Wiesen, Martin, additional, Koehler, Philipp, additional, A. Cornely, Oliver, additional, and Stemler, Jannik, additional

Published
2023
Full Text
View/download PDF

192. Duration of Protection From Pneumonia After Pneumococcal Vaccination in Hemodialysis Patients (DOPPIO): Protocol for a Prospective Multicenter Study

Author

Mellinghoff, Sibylle, primary, von Gersdorff, Gero, additional, Bruns, Caroline, additional, Albus, Kerstin, additional, Dimitriou, Vassiliki, additional, Steinbach, Angela, additional, Schaller, Mathias, additional, Vehreschild, Jörg Janne, additional, Cornely, Oliver A, additional, and Liss, Blasius Janusch, additional

Published
2023
Full Text
View/download PDF

196. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial

Author

Guery, Benoit, Menichetti, Francesco, Anttila, Veli-Jukka, Adomakoh, Nicholas, Aguado, Jose Maria, Bisnauthsing, Karen, Georgopali, Areti, Goldenberg, Simon D, Karas, Andreas, Kazeem, Gbenga, Longshaw, Chris, Palacios-Fabrega, Jose Alejandro, Cornely, Oliver A, and Vehreschild, Maria J G T

Published
2018
Full Text
View/download PDF

199. Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial

Author

Wunderink, Richard G., Giamarellos-Bourboulis, Evangelos J., Rahav, Galia, Mathers, Amy J., Bassetti, Matteo, Vazquez, Jose, Cornely, Oliver A., Solomkin, Joseph, Bhowmick, Tanaya, Bishara, Jihad, Daikos, George L., Felton, Tim, Furst, Maria Jose Lopez, Kwak, Eun Jeong, Menichetti, Francesco, Oren, Ilana, Alexander, Elizabeth L., Griffith, David, Lomovskaya, Olga, Loutit, Jeffery, Zhang, Shu, Dudley, Michael N., and Kaye, Keith S.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results